Goldman Sachs Makes Positive Comments on CVS (CVS) Ahead of Results
More News related to CVS
- The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against CVS Caremark Corporation
- Humana and CVS Caremark's MinuteClinic Expand Member Access to Convenient Quality Care
- MinuteClinic Opens First Retail Clinic in Washington, D.C. at CVS/pharmacy Store in Northeast
- Brower Piven Encourages Investors Who Have Losses in Excess of $300,000 From Investment in CVS Caremark Corporation to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsui
- CVS/pharmacy Kicks Off Annual Thanks and Giving(R) Campaign for the St. Jude Children's Research Hospital
More News related to Analyst Comments
- Interesting Call Buying In Research In Motion (RIMM)
- Broadpoint.AmTech Reiterates a 'Buy' on Marvell Technology (MRVL); Raises Estimates & PT
- Unemployment Data Brings Hope: Art Hogan Weighs In
- Brean Murray Maintains a 'Buy' on athenahealth (ATHN); Lofty Valuation Surpassed Only by Lofty Goals
- Benchmark Raises American Tower's (AMT) Price Target to $50 on Strong Tower Demand
Goldman Sachs issued positive comments today on CVS Caremark Corporation (NYSE: CVS) ahead of earnings due on Nov 5, reiterating their Conviction Buy List rating and $40 price target.
The firm sees EPS of $0.64, in-line with the consensus and at the high-end of co guidance; the firm sees the 2009 guidance range of $2.59-$2.64 to at least be maintained and possibly edged higher; and an update on the $2 billion share buyback, which could be approaching an end.
Related Categories
Analyst CommentsStocks Mentioned
-0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
